Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Neuropathology of Alzheimer's disease
The key pathological hallmarks—extracellular plaques and intracellular neurofibrillary
tangles (NFT)—described by Alois Alzheimer in his seminal 1907 article are still central to …
tangles (NFT)—described by Alois Alzheimer in his seminal 1907 article are still central to …
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
We describe a recently recognized disease entity, limbic-predominant age-related TDP-43
encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a …
encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a …
Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
Staging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration
could identify individuals at risk for cognitive decline in Alzheimer's disease (AD). In blood …
could identify individuals at risk for cognitive decline in Alzheimer's disease (AD). In blood …
NIA‐AA research framework: toward a biological definition of Alzheimer's disease
Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …
Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
Background Alzheimer's disease and its complications are the leading cause of death in
adults with Down syndrome. Studies have assessed Alzheimer's disease in individuals with …
adults with Down syndrome. Studies have assessed Alzheimer's disease in individuals with …
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Biomarkers have become an essential component of Alzheimer disease (AD) research and
because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used …
because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used …
[HTML][HTML] Defining imaging biomarker cut points for brain aging and Alzheimer's disease
CR Jack Jr, HJ Wiste, SD Weigand, TM Therneau… - Alzheimer's & …, 2017 - Elsevier
Introduction Our goal was to develop cut points for amyloid positron emission tomography
(PET), tau PET, flouro-deoxyglucose (FDG) PET, and MRI cortical thickness. Methods We …
(PET), tau PET, flouro-deoxyglucose (FDG) PET, and MRI cortical thickness. Methods We …
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Most neurodegenerative disorders are associated with aggregated protein deposits. In the
case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular …
case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular …
Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging
Importance Synaptic loss is well established as the major structural correlate of cognitive
impairment in Alzheimer disease (AD). The ability to measure synaptic density in vivo could …
impairment in Alzheimer disease (AD). The ability to measure synaptic density in vivo could …
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
Alzheimer's disease (AD) is characterized by two molecular pathologies: cerebral β-
amyloidosis in the form of β-amyloid (Aβ) plaques and tauopathy in the form of neurofibrillary …
amyloidosis in the form of β-amyloid (Aβ) plaques and tauopathy in the form of neurofibrillary …